November 2020 - Pharmaceutical Market Europe

November 2020 - Pharmaceutical Market Europe
Published on 12 November 2020

Description:

Creativity in quarantine, preparing for the next infectious disease, digital healthcare for chronic diseases and new product launches

Preview:

34 articles from this collection:
PME COVER
PME COVER
2 - OPEN Health
2 - OPEN Health
3 - Comment
3 - Comment
4 - SERVICEPLAN
4 - SERVICEPLAN
5 - Contents
5 - Contents
6-7 - News
6-7 - News
8-9 - Coronavirus news
8-9 - Coronavirus news
10-11 - Coronavirus news
10-11 - Coronavirus news
12 - Darwin’s medicine
12 - Darwin’s medicine
13 - Rohit Khanna
13 - Rohit Khanna
14 - Mike Dixon
14 - Mike Dixon
15 - Stephanie Hall
15 - Stephanie Hall
16-17 Rethinking our approach to infectious disease preparedness
16-17 Rethinking our approach to infectious disease preparedness
18-19 - Clinical research
18-19 - Clinical research
20-21 - US biosimilar market
20-21 - US biosimilar market
22 - Porterhouse Medical Group
22 - Porterhouse Medical Group
23 - Digitising healthcare
23 - Digitising healthcare
23 - PME - Pharma Market Europe Digitising healthcare
24-25 - Digital healthcare
24-25 - Digital healthcare
26 - 11 London and Teva UK
26 - 11 London and Teva UK
27 - yneos Health Communications
27 - yneos Health Communications
28 - First In Human Advert
28 - First In Human Advert
30-32 - Is creativity in quarantine?
30-32 - Is creativity in quarantine?
33 - Havas Lynx Group
33 - Havas Lynx Group
34 - Mednet Group
34 - Mednet Group
35 - Pegasus
35 - Pegasus
36 - Purple Agency
36 - Purple Agency
37 - PMEA Advert
37 - PMEA Advert
38-39 - How can virtual pharma companies de-risk new product launches?
38-39 - How can virtual pharma companies de-risk new product launches?
40-41 - Why digital is the solution to the healthcare crisis
40-41 - Why digital is the solution to the healthcare crisis
42-44 - Appointments
42-44 - Appointments
45 - Healthcare Comms News
45 - Healthcare Comms News
46 - Q&A
46 - Q&A
47 - Recruitment
47 - Recruitment
48 - Life
48 - Life